Streetbeat News

Analyst Ratings

REGN

Regeneron Pharmaceuticals Inc. (NASDAQ:REGN) stock has increased by 3.83% over the past month and by 29.37% over the past year. Despite this performance, its P/E ratio is lower than the aggregate P/E of the Biotechnology industry, which could indicate that the stock is undervalued or that shareholders do not expect future growth. Investors are advised to use the P/E ratio in conjunction with other financial metrics and qualitative analysis for investment decisions.

Portfolio Pulse from Benzinga Insights

July 28, 2023 | 4:15 pm

BFST

Stephens & Co. analyst Matt Olney maintains an Overweight rating on Business First Bancshares (NASDAQ:BFST) and raises the price target from $18 to $25.

Portfolio Pulse from jenniferd'souza@benzinga.com

July 28, 2023 | 4:13 pm

FAF

Stephens & Co. analyst John Campbell maintains an Overweight rating on First American Financial (NYSE:FAF) and raises the price target from $71 to $72.

Portfolio Pulse from jenniferd'souza@benzinga.com

July 28, 2023 | 4:11 pm

CFR

Stephens & Co. analyst Matt Olney maintains an Equal-Weight rating on Cullen/Frost Bankers (NYSE:CFR) and lowers the price target from $121 to $117.

Portfolio Pulse from jenniferd'souza@benzinga.com

July 28, 2023 | 4:10 pm

CVLG

Stephens & Co. analyst Jack Atkins maintains an Overweight rating on Covenant Logistics Gr (NASDAQ:CVLG) and raises the price target from $63 to $70.

Portfolio Pulse from jenniferd'souza@benzinga.com

July 28, 2023 | 4:08 pm

BFST

Business First Bancshares reported better-than-expected Q2 financial results, leading to a rise in its stock price. Raymond James upgraded the stock from Market Perform to Outperform and set a $20 price target.

Portfolio Pulse from Benzinga Newsdesk

July 28, 2023 | 4:05 pm

NYCB

JP Morgan has upgraded New York Community Bancorp's stock from Neutral to Overweight, leading to a rise in the company's share prices.

Portfolio Pulse from Benzinga Newsdesk

July 28, 2023 | 4:03 pm

CX

JP Morgan has maintained an Overweight rating on Cemex's stock and increased its price target from $8 to $9. This has led to a rise in Cemex's share price.

Portfolio Pulse from Benzinga Newsdesk

July 28, 2023 | 4:03 pm

RETA

Stifel analyst Annabel Samimy has downgraded Reata Pharmaceuticals from Buy to Hold, while raising the price target from $110 to $172.5.

Portfolio Pulse from richadhand@benzinga.com

July 28, 2023 | 4:01 pm

CHDN

Over the past 3 months, 8 analysts have published their opinion on Churchill Downs (NASDAQ:CHDN) stock. The average price target is $154.88, implying an upside from the current price of $118.99. This average has decreased by 2.35% from the previous average price target of $158.60.

Portfolio Pulse from Benzinga Insights

July 28, 2023 | 4:01 pm